-
公开(公告)号:US4274978A
公开(公告)日:1981-06-23
申请号:US101341
申请日:1979-12-07
申请人: Edwin G. Moore
发明人: Edwin G. Moore
CPC分类号: G01N33/96 , G01N33/723 , G01N2333/805 , Y10T436/104998 , Y10T436/105831 , Y10T436/107497 , Y10T436/108331
摘要: This invention encompasses a standard for determining glycosylated hemoglobin comprising a mixture of hemoglobin or methemoglobin and about 1% to 25% of the 2,4-dinitrophenyl derivative of hemoglobin or methemoglobin wherein a 2,4-dinitrophenyl group blocks the allosteric binding site of hemoglobin or methemoglobin.
摘要翻译: 本发明包括用于测定糖基化血红蛋白的标准,其包含血红蛋白或高铁血红蛋白的混合物和血红蛋白或高铁血红蛋白的2,4-二硝基苯基衍生物的约1%至25%,其中2,4-二硝基苯基阻断血红蛋白的变构结合位点 或高铁血红蛋白。
-
公开(公告)号:US07211560B2
公开(公告)日:2007-05-01
申请号:US10747580
申请日:2003-12-29
申请人: Douglas L. Looker , Izydor Z. Apostol , Eric A. Brucker , Michael P. Doyle , David L. Foster , Christopher B. Glascock , James C. Hartman , Geoffrey F. Lee , Douglas D. Lemon , Edwin G. Moore , Jane P. Richards , Michael R. Schick , Stephen P. Trimble , David Pereira , Ton-That Hai , Kenneth E. Burhop
发明人: Douglas L. Looker , Izydor Z. Apostol , Eric A. Brucker , Michael P. Doyle , David L. Foster , Christopher B. Glascock , James C. Hartman , Geoffrey F. Lee , Douglas D. Lemon , Edwin G. Moore , Jane P. Richards , Michael R. Schick , Stephen P. Trimble , David Pereira , Ton-That Hai , Kenneth E. Burhop
IPC分类号: A61K35/14
CPC分类号: C07K14/805 , A61K38/00
摘要: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
摘要翻译: 本发明涉及新型血红蛋白组合物,特别是新型重组突变体血红蛋白组合物,其消除或显着减少1)心脏病变的产生,2)胃肠道不适,3)加压作用,和4)与施用细胞外血红蛋白相关的内毒素超敏反应 各种治疗应用中的组合物。 描述的应用包括贫血,头部损伤,出血或血容量不足,局部缺血,恶病质,镰状细胞危象和中风的治疗。 加强癌症治疗; 刺激造血; 改善身体损伤组织的修复; 减轻心源性休克; 和休克复苏。
-
公开(公告)号:US4255385A
公开(公告)日:1981-03-10
申请号:US87367
申请日:1979-10-23
申请人: Stephen D. Stroupe , Edwin G. Moore
发明人: Stephen D. Stroupe , Edwin G. Moore
IPC分类号: G01N33/72
CPC分类号: G01N33/723
摘要: A method, reagent and test kit for determining glycosylated hemoglobin in blood samples which involves liberating hemoglobins from red blood cells by chemical or physical means and reacting non-glycosylated hemoglobin with an allosteric site binding substance which reacts with the allosteric binding site of non-glycosylated hemoglobin and thereby alters the distribution between allosteric forms of the hemoglobins and measuring the change. This method is useful in monitoring glucose metabolism for detecting and controlling diabetes.
摘要翻译: 一种用于测定血液样品中糖基化血红蛋白的方法,试剂和测试试剂盒,其包括通过化学或物理方法从红血细胞释放血红蛋白,并使非糖基化血红蛋白与变构位点结合物质反应,所述变构位点结合物质与非糖基化的变构结合位点反应 血红蛋白,从而改变血红蛋白的变构形式之间的分布并测量变化。 该方法可用于监测葡萄糖代谢以检测和控制糖尿病。
-
公开(公告)号:US4260516A
公开(公告)日:1981-04-07
申请号:US101353
申请日:1979-12-07
申请人: Edwin G. Moore
发明人: Edwin G. Moore
CPC分类号: G01N33/723 , Y10T436/105831 , Y10T436/107497 , Y10T436/108331
摘要: This invention encompasses a standard for determining glycosylated hemoglobin comprising a mixture of hemoglobin or methemoglobin and about 1% to 25% of the N-[5-nitrotropon-2-yl] hemoglobin or methemoglobin derivative wherein the allosteric binding site is blocked.
摘要翻译: 本发明包括用于测定糖基化血红蛋白的标准,其包含血红蛋白或高铁血红蛋白的混合物和约1%至25%的N- [5-硝基丙酮-2-基]血红蛋白或高铁血红蛋白衍生物,其中变构结合位点被阻断。
-
公开(公告)号:US4200435A
公开(公告)日:1980-04-29
申请号:US973368
申请日:1978-12-26
申请人: Stephen D. Stroupe , Edwin G. Moore
发明人: Stephen D. Stroupe , Edwin G. Moore
CPC分类号: G01N33/723 , H04M19/04
摘要: A method for determining glycosylated hemoglobin in blood samples which involves liberating hemoglobins from red blood cells by chemical or physical means and reacting non-glycosylated hemoglobin with an allosteric site binding substance which reacts with the allosteric binding site of non-glycosylated hemoglobin and thereby alters the distribution between allosteric forms of the hemoglobins and measuring the change. This method is useful in monitoring glucose metabolism for detecting and controlling diabetes.
摘要翻译: 一种用于测定血液样品中糖基化血红蛋白的方法,其包括通过化学或物理方法从红细胞释放血红蛋白,并使非糖基化血红蛋白与与非糖基化血红蛋白的变构结合位点反应的变构位点结合物质反应,从而改变 分布在变性形式的血红蛋白和测量变化。 该方法可用于监测葡萄糖代谢以检测和控制糖尿病。
-
公开(公告)号:US06670323B1
公开(公告)日:2003-12-30
申请号:US09709914
申请日:2000-11-10
申请人: Douglas L. Looker , Izydor Z. Apostol , Eric A. Brucker , Michael P. Doyle , David L. Foster , Christopher B. Glascock , James C. Hartman , Geoffrey F. Lee , Douglas D. Lemon , Edwin G. Moore , Jane P. Richards , Michael R. Schick , Stephen P. Trimble , David Pereira , Ton-That Hai , Kenneth E. Burhop
发明人: Douglas L. Looker , Izydor Z. Apostol , Eric A. Brucker , Michael P. Doyle , David L. Foster , Christopher B. Glascock , James C. Hartman , Geoffrey F. Lee , Douglas D. Lemon , Edwin G. Moore , Jane P. Richards , Michael R. Schick , Stephen P. Trimble , David Pereira , Ton-That Hai , Kenneth E. Burhop
IPC分类号: C07K14805
CPC分类号: C07K14/805 , A61K38/00
摘要: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
摘要翻译: 本发明涉及新型血红蛋白组合物,特别是新型重组突变体血红蛋白组合物,其消除或显着减少1)心脏病变的产生,2)胃肠道不适,3)加压作用,和4)与施用细胞外血红蛋白相关的内毒素超敏反应 各种治疗应用中的组合物。 描述的应用包括贫血,头部损伤,出血或血容量不足,局部缺血,恶病质,镰状细胞危象和中风的治疗。 加强癌症治疗; 刺激造血; 改善身体损伤组织的修复; 减轻心源性休克; 和休克复苏。
-
-
-
-
-